Introduction
Of the roughly 150,000 new infections of coccidioidomycosis (Valley Fever) that occur each year, there is an enormous range of severity and outcomes. As depicted in the gure, approximately a third seek medical attention because of a signi cant illness and even fewer of these are accurately diagnosed and reported to state o cials. 1 e community-acquired pneumonia syndrome that most symptomatic patients experience often takes many weeks to many months to completely resolve and is anything but trivial. 2 Even so, for most patients, the illness is eventually self-limited whether treated or not.
In contrast, a relatively small proportion of all infections result in the spread through the blood stream beyond the lungs (extrathoracic dissemination) to produce progressive tissue destruction in skin, bones, joints, the central nervous system, and almost any other part of the body. As a result, about 160 persons die of Valley Fever each year. 3 What accounts for this striking spectrum of disease has been the subject of speculation for decades. Now two research programs have been initiated to try to answer this question.
Genetic differences among persons is the prime suspect
For many infectious diseases, the size of the microbial inoculum determines whether disease will result. Indeed, there are very good examples of this when the exposure to coccidioidal spores is very high. For example, when archeologists or construction projects involve soil rich in spores of Coccidioides spp., infection rates are higher and symptomatic illness is more common than found in the general population within endemic regions. 4-6 However, in such clusters, there is little or no evidence that high inoculum is more likely to result in extrathoracic dissemination.
Another possible source of di erences in disease severity could be due to di erences among strains of Coccidioides spp. While this cannot be entirely ruled out, the evidence that exists is not supportive. For example, in the clusters of infections cited above where likely most infections came from genetically similar spores, there is still a wide spectrum of illness. Similarly, in laboratory accidents where all persons are de nitely exposed to the same strain, there are also diverse clinical manifestations. 7 
How does genetics influence Valley
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In contrast to inoculum and fungal virulence, several lines of evidence implicate genetic di erences among individuals as a factor responsible for disseminated infection. First and most apparent, normal control of coccidioidal infection is critically dependent on competent cellular immunity. When this is severely compromised either by an underlying disease such as AIDS 8, 9 or by immunosuppression for organ transplantation or treatment of autoimmune disorders, 10-12 coccidioidal infections are very much more likely to result in extrathoracic dissemination. at broad immunosuppression is a major risk factor for disseminated Valley Fever opens up the possibility that more subtle di erences in the immune response to coccidioidal infection could account for di erences in disease severity.
Secondly, men are much more likely to develop disseminated coccidioidal infection than women. Evidence for this comes from the enrollment statistics for clinical trials conducted by the Mycoses Study Group for patients with disseminated coccidioidal infection where between 1988 and 2007 three-quarters of 367 subjects were male. [13] [14] [15] [16] [17] Similar results are apparent in other reports as well. [18] [19] [20] irdly, at least one speci c genetic marker, that of B and AB blood groups, has been associated with disseminated infection. 19, 21 is is not likely to be a causal relationship but does clearly suggest a genetic component.
Finally, numerous studies have implicated increased risk of certain ethnic groups for disseminated infection, most notably those of African and Filipino ancestry. 22 Estimates of how much more susceptible African-Americans are to developing disseminated disease range as high as 41.9 times more than Caucasians (Table  1 ). An ADHS presentation in 2011 based upon chart review of reported cases found dissemination in Blacks was 25% compared to 6% in Whites, roughly a four-fold increase in incidence of dissemination. e denominator for these statistics was all cases reported to the state and therefore avoid referral bias and some other confounding factors in earlier studies.
Despite all of these associations suggesting a genetic component to a risk for disseminated infection, there have been essentially no observations as to which speci c genes are involved and how genetic di erences a ect disease susceptibility. Dr.
Stephen Holland, a physician scientist and his colleagues at the National Institutes for Health have recently identi ed in a small number of patients speci c gene mutations which appear responsible for more severe infections. e mutated genes were the interferongamma receptor 1, 28 the interleukin-12 receptor beta, 29 and STAT1. 30 As important as these ndings are, all of the patients described in these reports are not typical of most patients who experience disseminated coccidioidomycosis. e patient with the interferongamma receptor 1 de ciency had two other opportunistic mycobacterial infections at other times in his life, and multiple opportunistic infections are not typical for patients with disseminated Valley Fever. e patients with the interleukin-12 beta de ciency were siblings from a consanguineous family. Disseminated coccidioidomycosis is very uncommon in multiple members of the same family. e two patients with the STAT1 mutation had a clinical presentation that included disseminated infection but also included a consumptive pulmonary process that was strikingly devoid of cavitation. However, Dr. Holland has identi ed additional patients who appear to have functional immunologic de cits, even thought he and his team were unable to determine the genetic basis for those altered responses. 31
Two Studies now underway involving Arizonans to better understand the genetics of disseminated Valley Fever
Encouraged by his recent ndings, Dr. Holland has written a clinical research protocol speci cally addressing patients is open to any person over the age of 2 years who has culture or histologic proof of disseminated Valley Fever. Persons who have an already identi ed immunosuppressing condition or who have a medical or psychiatric condition that would interfere with providing informed consent would not be appropriate for this study. If informed consent is given, subjects will initially have blood specimens collected locally for shipment to the NIH. en, depending upon initial results, subjects may be invited to visit the NIH for additional testing. After the initial visit, study related expenses, including travel and treatment of the disseminated Valley Fever infection, will be paid by the NIH (initial travel expenses may be covered for indigent subjects). Dr. Holland's study is open to patients throughout the United States. However, for those close enough to down town Phoenix, it will be possible to have the initial blood and urine specimens obtained and shipment arranged by the NIH laboratory located on the Indian Health Hospital campus.
is protocol was initiated in the fall of 2014 and is currently active.
A second research initiative is investigating the increased susceptibility of those with African ancestry. Despite the ndings shown in Table  1 above, an underlying problem with all estimates of increased frequency of disseminated coccidioidomycosis in African-Americans is that the relation of self-identi ed race/ethnicity (SIRE) is a poor surrogate for ancestral genetic origins. Genetic heterogeneity within each racial and ethnic grouping may bias associations in genetic association studies, generating both false-positive and false-negative results. [32] [33] [34] [35] [36] Variations in the distribution of single nucleotides polymorphisms (SNPs), called ancestry informative markers (AIMs), have been found which describe the architecture of genome variations between populations. 37 is discovery has led to an approach which circumvents the genetic ambiguity of SIRE categorizations. One of the bene ts of AIMs is that relatively few markers are required (about 1,500 AIMs for African-Americans) to e ectively screen the entire genome. As such, we expect it to identify large chromosomal regions of di erential ethnic ancestry in clinical samples.
For this second study, anyone who is self-declared of African ancestry who has laboratory con rmed coccidioidal infection is eligible. For those who have not experienced disseminated infection, an adequate length of time o antifungal therapy is necessary (nominally two years 38 ) to determine if disseminated infection is not likely to occur. Consenting subjects will be asked for a sample of saliva for genetic testing.
ey may also be asked for a blood specimen in the future for laboratory studies of their leukocyte response to coccidioidal antigens. Collaborators for this study are in both Phoenix and in Tucson. 
Summary
